CJC-1295: A Long-Acting GHRH Analog That Normalizes GH With Once-Daily Dosing
CJC-1295, a long-acting GHRH analog, normalized growth hormone secretion in GH-deficient rats with once-daily dosing, demonstrating sustained GH-axis restoration that could simplify GH deficiency treatment.
Quick Facts
What This Study Found
CJC-1295 (long-acting GHRH analog with extended half-life through DPP-IV resistance) normalized pulsatile GH secretion and IGF-1 in GH-deficient rats with once-daily SC administration — practical sustained GH-axis restoration for potential clinical simplification.
Key Numbers
How They Did This
animal-study study on cjc-1295, hormone-optimization.
Why This Research Matters
Relevant for cjc-1295, hormone-optimization.
The Bigger Picture
Advances peptide research.
What This Study Doesn't Tell Us
See abstract.
Questions This Raises
- ?Further research needed.
- ?Clinical translation to evaluate.
Trust & Context
- Key Stat:
- Key finding CJC-1295 (long-acting GHRH analog with extended half-life through DPP-IV resistance) normalized pulsatile GH secretion and IGF-1 in GH-deficient rats
- Evidence Grade:
- moderate evidence.
- Study Age:
- Published in 2006.
- Original Title:
- Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.
- Published In:
- American journal of physiology. Endocrinology and metabolism, 291(6), E1290-4 (2006)
- Authors:
- Alba, Maria(2), Fintini, Danilo(2), Sagazio, Alessia, Lawrence, Betty, Castaigne, Jean-Paul, Frohman, Lawrence A, Salvatori, Roberto
- Database ID:
- RPEP-01113
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What was studied?
CJC-1295: A Long-Acting GHRH Analog That Normalizes GH With Once-Daily Dosing
What was found?
CJC-1295, a long-acting GHRH analog, normalized growth hormone secretion in GH-deficient rats with once-daily dosing, demonstrating sustained GH-axis restoration that could simplify GH deficiency treatment.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-01113APA
Alba, Maria; Fintini, Danilo; Sagazio, Alessia; Lawrence, Betty; Castaigne, Jean-Paul; Frohman, Lawrence A; Salvatori, Roberto. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.. American journal of physiology. Endocrinology and metabolism, 291(6), E1290-4.
MLA
Alba, Maria, et al. "Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.." American journal of physiology. Endocrinology and metabolism, 2006.
RethinkPeptides
RethinkPeptides Research Database. "Once-daily administration of CJC-1295, a long-acting growth ..." RPEP-01113. Retrieved from https://rethinkpeptides.com/research/alba-2006-oncedaily-administration-of-cjc1295
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.